UnitedHealth Group reported strong third-quarter results with 9% revenue growth and a 23% increase in adjusted EPS, raising full-year earnings guidance. Management highlighted continued momentum across all business segments, particularly in Optum and UnitedHealthcare, and expressed optimism for sustained growth into 2018 and beyond. Despite acknowledging headwinds like the reinstatement of the health insurance tax, the company's positive performance and outlook are likely to have a positive impact on the stock price in the short term.

[1]